US drugmakers Pfizer and Upjohn both announced stock programs last month. Pfizer said it was putting a proposal to shareholders for a two-for-one stock split on April 27.
Upjohn's board increased the authorization for the repurchase of up to an additional nine million shares of the company's stock, equivalent to around $300 million at current market prices. The company has already completed one-third of a December 1991, nine and a half million share repurchase authorization, and the nine million now announced raises the total common shares authorized for repurchase to 15 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze